Frontlight ResearchEarly access
TerminatedNo phase
Evaluation of the Microbiome in Multiple Sclerosis
Key facts
- Who runs it
- Nimble Science Ltd.
- Where
- Canada1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Terminated
- People taking part
- 40 people enrolled
- Started
- 26 Jun 2023
- Ended
- 24 Apr 2024
- Type of study
- Interventional
- Treatments tested
- SIMBA Capsule
- Record updated
- 15 May 2025
- Why it stopped
- Financial constraints and study recruitment phase exceeded the time allotted
Who can take part
- Age
- 18 years to 80 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Age between 18 and 60 years inclusive
- Have diagnosis of Multiple Sclerosis (relapsing remitting or secondary progressive for the MS cohort) or be a healthy individual living in the same household (non-MS for the healthy control cohort)
- No antibiotics, or colon cleanses/bowel preparation in the previous 2 weeks
- Written informed consent
Who cannot take part
- Known disease which, in the investigator's opinion, would lead to intestinal stricture or obstruction with a risk of capsule non-excretion (particular diseases which would be assessed on a case-by-case basis would include, achalasia, eosinophilic esophagitis, diverticulitis, Crohn's disease, Ulcerative colitis, cancer diagnosis or treatment within the past year, or previous oesophageal, gastric, small intestinal, or colonic surgery. 3) Appendectomy or cholecystectomy more than 3 months prior to enrolment are acceptable). The main deciding factor would be history of obstructive symptoms in the previous 3 months prior to entry
- Use of any medications in the previous week that could substantially alter gastrointestinal motor function (e.g., opioids, prokinetics, anticholinergics, laxatives), or acidity (PPI, H2RA); for both groups
- Known to have swallowing disorders
- < 2 bowel movements per week (for both groups)
- Risk or suspect of being pregnant
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
To access the small intestinal microbiome and find abnormal microbiome/metabolome signature in luminal fluid samples from small bowel in MS compared to HC that could be used as biomarkers for MS.
The group in the trial
- Single ArmTreatment being tested
Participant swallows and retrieves capsule in stool. Intestinal fluid samples collected by SIMBA capsules from the MS and HC participants, along with a fecal and blood samples, will be used for gut microbiome, viral and metabolomic analysis.
Treatment: SIMBA Capsule
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- A Clinical Study To Evaluate Small Intestine Microbiome In Multiple Sclerosis (MS)
- Record updated
- 15 May 2025